March 20, 2019 06:56 AM EDTUpdated 04:49 PM
R&D

Glax­o­SmithK­line sets its sights on a quick leap in­to the big PD-1/L1 game — will any­one no­tice?

John Carroll

Editor & Founder

Some­what lost in the news last fall that Glax­o­SmithK­line was buy­ing Tesaro and leap­ing in­to the com­mer­cial end of the chal­leng­ing PARP mar­ket was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times